11.71
11.71 (0%)
As of Feb 14, 2025
Surrozen, Inc. [SRZN]
Source:
Company Overview
Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-specific Wnt candidates.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | 650-475-2820 |
Industry | |
CEO | Craig Parker |
Website | www.clinicaltrials.gov |